From Surf Wiki (app.surf) — the open knowledge base
Ergotamine/caffeine
Pharmaceutical product
Pharmaceutical product
| Field | Value |
|---|---|
| type | combo |
| component1 | Ergotamine |
| class1 | vasoconstrictor, neurotransmitter agonist and antagonist |
| component2 | Caffeine |
| class2 | vasoconstrictor, phosphodiesterase inhibitor |
| tradename | Cafergot, Migergot, others |
| Drugs.com | |
| MedlinePlus | a601048 |
| DailyMedID | Ergotamine and caffeine |
| pregnancy_AU | C |
| pregnancy_category | Contraindicated |
| routes_of_administration | By mouth, rectal |
| ATC_prefix | N02 |
| ATC_suffix | CA52 |
| legal_AU | |
| legal_BR | |
| legal_CA | |
| legal_DE | |
| legal_NZ | |
| legal_UK | |
| legal_US | Rx-only |
| legal_US_comment | |
| legal_UN | |
| legal_status | |
| CAS_number | 69063-86-1 |
| KEGG | D07600 |
| Drugs.com =
Ergotamine/caffeine, sold under the brand name Cafergot among others, is a fixed-dose combination medication used for the treatment of migraine. It contains ergotamine, as the tartrate, an alpha adrenergic blocking agent; and caffeine, a cranial vasoconstrictor.
Ergotamine/caffeine is available as a generic medication.
Medical uses
Ergotamine/caffeine is indicated as therapy to abort or prevent vascular headache.
Mechanism of action
Ergotamine binds to 5-HT1B and 5-HT1D receptors. This along with binding to other serotonergic and dopaminergic receptors is their presumed mechanism of action in treating migraine.
Adverse effects
Because the vasoconstrictive effects of ergotamine and caffeine are not selective for the brain, adverse effects due to systemic vasoconstriction can occur. Cold feet or hands, angina pectoris, myocardial infarction, or dizziness are some examples.
It has also been shown to be associated with mitral valve stenosis.
References
References
- "Cafergot- ergotamine tartrate and caffeine tablet, film coated". U.S. National Library of Medicine.
- (29 November 2022). "Migergot- ergotamine tartrate and caffeine suppository".
- (2002). "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison". European Neurology.
- (15 January 2018). "Acute treatment of migraine in adults". [[Wolters Kluwer]].
- (November 1976). "Ergotamine and methysergide as serotonin partial agonists in migraine". Headache.
- (2006). "The Headaches". Lippincott Williams and Wilkins.
- (October 1993). "Mitral valve disease associated with long-term ergotamine use". Southern Medical Journal.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Ergotamine/caffeine — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report